# Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

> **NCT06437353** · PHASE2 · RECRUITING · sponsor: **Anhui Provincial Cancer Hospital** · enrollment: 74 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06437353
- **Lead sponsor:** Anhui Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-25
- **Primary completion:** 2025-10-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2024-11-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06437353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06437353, "Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06437353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*